The Pistoia Alliance's recent poll conducted during the Clinical Trials Technology Congress sheds light on the industry's readiness for AI adoption and the regulatory landscape surrounding it.
In a live audience poll at the Congress, regulators from various European agencies gathered insights on the industry's sentiment toward AI in clinical research. The results highlighted significant barriers to AI adoption, including trust and regulatory uncertainty, while also indicating that the regulatory bodies are open to AI technologies, provided their implementation is safe and transparent. This underscores the importance of early engagement with regulators to ensure a unified approach to technology adoption in clinical trials.
The poll revealed that 42% of participants have begun to see early returns on investment (ROI) from AI, with an additional 23% expecting ROI in the future. Companies are increasingly focusing on operational efficiencies rather than just direct cost savings. Key metrics such as faster enrollment and reduced data queries were cited as indicators of AI's impact. Respondents anticipate that AI will primarily enhance data cleaning and analysis, as well as patient sourcing and engagement, suggesting a shift towards more strategic applications of AI in clinical trials.
Furthermore, the poll indicated that 60% of respondents are utilizing patient-generated data, with social media listening becoming a valuable tool for understanding patient needs and experiences. This trend points to a broader acceptance of diverse data sources beyond traditional clinical trial data, allowing for a more holistic view of patient experiences. As the industry navigates these advancements, the Pistoia Alliance aims to establish standards to ensure ethical use of AI in clinical settings while addressing privacy concerns.
Overall, the findings from the Pistoia Alliance's poll highlight a pivotal moment for AI in clinical research, suggesting that as stakeholders align their expectations and regulatory frameworks evolve, the potential for AI to transform the clinical landscape is significant.